Table 2 Potency (relative to S1) and EC50 estimates for samples XC, C1, C2 and C3
From: The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum
Antigen | Sample | |||
|---|---|---|---|---|
XC | C1 | C2 | C3 | |
A. Potency relative to S1: Between-laboratory geometric mean and geometric coefficient of variation (%) after exclusion of laboratories 2, 3, 4 and 13 | ||||
AMA-1 | 0.809 (9.6%) | 3.549 (8.2%) | 0.870 (5.7%) | 0.014 (12.5%) |
MSP-142 | 0.493 (8.3%) | 2.447 (8.4%) | 0.871 (6.6%) | 0.033 (11.5%) |
MSP-3 | 0.548 (7.9%) | 3.026 (6.2%) | 0.812 (5.4%) | 0.041 (13.9%) |
B. EC 50 estimates: Between-laboratory geometric mean and geometric coefficient of variation (%) after exclusion of laboratories 2, 3, 4 and 13 | ||||
AMA-1 | 0.071 (79.7%) | 0.016 (62.4%) | 0.069 (69.5%) | 3.849 (82.7%) |
MSP-142 | 0.309 (52.8%) | 0.061 (48.1%) | 0.167 (56.0%) | 4.406 (46.6%) |
MSP-3 | 0.620 (60.6%) | 0.108 (63.9%) | 0.441 (53.6%) | 7.892 (62.0%) |